Candriam SCA’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-393,390
| Closed | -$7.93M | – | 894 |
|
|
2021
Q3 | $7.93M | Sell |
393,390
-24,855
| -6% | -$686K | 0.05% | 316 |
|
|
2021
Q2 | $15.6M | Sell |
418,245
-990,748
| -70% | -$30.4M | 0.11% | 222 |
|
|
2021
Q1 | $29.8M | Hold |
1,408,993
| – | – | 0.25% | 107 |
|
|
2020
Q4 | $31M | Buy |
1,408,993
+199,787
| +17% | +$4.4M | 0.25% | 107 |
|
|
2020
Q3 | $21.8M | Sell |
1,209,206
-134,063
| -10% | -$2.78M | 0.2% | 126 |
|
|
2020
Q2 | $34.1M | Buy |
1,343,269
+463,769
| +53% | +$9.99M | 0.36% | 65 |
|
|
2020
Q1 | $18.9M | Hold |
879,500
| – | – | 0.21% | 109 |
|
|
2019
Q4 | $19.4M | Buy |
879,500
+160,000
| +22% | +$3.22M | 0.21% | 109 |
|
|
2019
Q3 | $10.3M | Buy |
+719,500
| New | +$10.3M | 0.14% | 177 |
|
|
2019
Q2 | – | Sell |
-447,500
| Closed | -$6.09M | – | 192 |
|
|
2019
Q1 | $6.56M | Hold |
447,500
| – | – | 0.08% | 268 |
|
|
2018
Q4 | $4.78M | Buy |
447,500
+156,000
| +54% | +$2.05M | 0.07% | 290 |
|
|
2018
Q3 | $4.45M | Buy |
+291,500
| New | +$4.24M | 0.06% | 342 |
|
|
2015
Q3 | – | Sell |
-105,000
| Closed | -$1.47M | – | 652 |
|
|
2015
Q2 | $1.47M | Sell |
105,000
-40,000
| -28% | -$734K | 0.03% | 397 |
|
|
2015
Q1 | $3.48M | Buy |
145,000
+35,000
| +32% | +$787K | 0.07% | 313 |
|
|
2014
Q4 | $1.81M | Buy |
+110,000
| New | +$1.27M | 0.04% | 368 |
|
Other funds holding DRNA
Candriam SCA's DRNA Position: Q4 2021 in Review
Candriam SCA sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 393,390 shares — an estimated $7.93M sold.
Candriam SCA first reported a position in DRNA in Q4 2014 and held it in 15 quarters. The position peaked at $34.1M in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Candriam SCA reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Candriam SCA sold 393,390 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $7.93M.
- Candriam SCA first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2014 and held it in 15 quarters.
- Candriam SCA's Dicerna Pharmaceuticals, Inc. position peaked at $34.1M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.